576 related articles for article (PubMed ID: 22265638)
1. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.
Namazi S; Kojuri J; Khalili A; Azarpira N
Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638
[TBL] [Abstract][Full Text] [Related]
2. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.
Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
JACC Cardiovasc Interv; 2008 Dec; 1(6):620-7. PubMed ID: 19463375
[TBL] [Abstract][Full Text] [Related]
3. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
4. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Isordia-Salas I; Olalde-Román MJ; Santiago-Germán D; de la Peña NC; Valencia-Sánchez JS
Thromb Res; 2012 Sep; 130(3):e67-72. PubMed ID: 22819265
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
6. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
7. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: effects on clopidogrel response.
Shalia KK; Shah VK; Pawar P; Divekar SS; Payannavar S
Indian Heart J; 2013; 65(2):158-67. PubMed ID: 23647895
[TBL] [Abstract][Full Text] [Related]
9. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
[TBL] [Abstract][Full Text] [Related]
10. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
[TBL] [Abstract][Full Text] [Related]
11. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.
Gurbel PA; Bliden KP; Antonino MJ; Stephens G; Gretler DD; Jurek MM; Pakyz RE; Shuldiner AR; Conley PB; Tantry US
J Thromb Haemost; 2010 Jan; 8(1):43-53. PubMed ID: 19817997
[TBL] [Abstract][Full Text] [Related]
12. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement.
Hochholzer W; Trenk D; Fromm MF; Valina CM; Stratz C; Bestehorn HP; Büttner HJ; Neumann FJ
J Am Coll Cardiol; 2010 Jun; 55(22):2427-34. PubMed ID: 20510210
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of response to clopidogrel and cardiovascular events.
Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
[TBL] [Abstract][Full Text] [Related]
14. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.
Sun B; Li J; Dong M; Yang L; Wu C; Zhu L; Cong YL
Genet Mol Res; 2015 Feb; 14(1):1434-42. PubMed ID: 25730082
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.
Siller-Matula JM; Delle-Karth G; Lang IM; Neunteufl T; Kozinski M; Kubica J; Maurer G; Linkowska K; Grzybowski T; Huber K; Jilma B
J Thromb Haemost; 2012 Apr; 10(4):529-42. PubMed ID: 22260716
[TBL] [Abstract][Full Text] [Related]
16. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.
Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H
Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934
[TBL] [Abstract][Full Text] [Related]
18. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults.
Sridharan K; Kataria R; Tolani D; Bendkhale S; Gogtay NJ; Thatte UM
Indian J Pharmacol; 2016; 48(4):350-354. PubMed ID: 27756942
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
